FSD PHARMA TO ESTABLISH PRESENCE IN CANADA'S INSURANCE REGIMES
March 28 2019 - 7:30AM
InvestorsHub Cannabis NewsWire
FSD
PHARMA TO ESTABLISH PRESENCE IN CANADA’S
INSURANCE REGIMES
Signs
agreement focusing on exploring insurance coverage for medical
cannabis Canada wide
TORONTO, ON --
March 28,
2019 -- InvestorsHub NewsWire
-- FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the
"Company"), announced today the signing of a consulting
agreement with Joseph L. Romano, a well-respected lawyer with a
strong track-record in personal injury law. Mr. Romano has been
working with medical cannabis since 2006, assisting people coping
with chronic pain to have access to medical cannabis, a viable
alternative to opioid based medications.
Pursuant to the terms of the agreement, Mr.
Romano will provide consulting on the inner workings of third party
actions, wsib claim handling, first party coverage and no fault
benefits across Canada. Mr. Romano will also assist in identifying
strategic acquisitions that will enhance shareholder
value.
Commenting on the agreement, Dr. Raza Bokhari,
Executive Co-Chairman and interim CEO said, “We are very excited to
engage Mr. Romano in advance of our anticipated sales license. This
is a very timely and important agreement for FSD Pharma to maximize
the opportunities in the Canadian market for our products and fits
well with our strategy of establishing the company as a leader in
medical cannabis.”
In consideration for his services, FSD will pay
Mr. Romano consulting fees, warrants and shares in the company,
subject to compliance with all applicable securities laws and the
policies of the Canadian Securities Exchange.
About FSD Pharma
FSD Pharma is focused on the development of the
highest quality indoor grown, pharmaceutical grade cannabis and on
the research and development of novel cannabinoid-based treatments
for several central nervous system disorders, including chronic
pain, fibromyalgia and irritable bowel syndrome. The Company has
25,000 square feet available for production at its Ontario facility
with an additional 220,000 square feet currently in development
(with an estimated cost of $250 per square foot to be completed in
2019).
FSD facilities sit on 72 acres of land with 40
acres primed for development and an expansion capability of up to
3,896,000 square feet.
FSD's wholly-owned subsidiary, FV Pharma, is a
licensed producer under the Cannabis Act and Regulations,
having received its cultivation license on October 13, 2017. FV
Pharma's vision is to transform its current headquarters in a Kraft
plant in Cobourg, Ontario into the largest hydroponic indoor grow
facility in the world. FV Pharma intends to cover all aspects of
this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and
development.
Forward-Looking
Information
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press
release constitute forward-looking information. These statements
relate to future events or future performance. The use of any of
the words “could”, “intend”, “expect”, “believe”, “will”,
“projected”, “estimated” and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on FSD Pharma’s
current belief or assumptions as to the outcome and timing of such
future events. Actual future results may differ materially. Actual
results and developments may differ materially from those
contemplated by these. The forward-looking information contained in
this press release is made as of the date hereof, and FSD Pharma is
not obligated to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise,
except as required by applicable securities laws. Because of the
risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking
information contained herein.
For further
information:
Zeeshan Saeed, President, Founder and Director,
FSD Pharma Inc., Email: zeeshan@fsdpharma.com, Telephone:
(416) 854-8884
Investor Relations: Email: ir@fsdpharma.com, Website: www.fsdpharma.com
Media Relations: Nic Johnson, Email:
nic.johnson@russopartnersllc.com,
Tel: (212) 845-4242
FSD Pharma (CSE:HUGE)
Historical Stock Chart
From Sep 2024 to Oct 2024
FSD Pharma (CSE:HUGE)
Historical Stock Chart
From Oct 2023 to Oct 2024